合肥立方制药股份有限公司 经核查独立董事的任职经历及签署的相关自查文件，董事会认为公司独立董 事杨模荣、李进华、史静不存在《上市公司独立董事管理办法》第六条规定的不 得担任独立董事的情形，与公司以及主要股东之间不存在妨碍其进行独立客观判 断的关系，不存在影响独立董事独立性的情况，符合《上市公司独立董事管理办 法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等法律法规及《公司章程》中关于独立董事的任职资格及独立性的相关要求。 合肥立方制药股份有限公司 董事会 2025 年 4 月 18 日 董事会关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》等规定，合肥立方制药股份有限公司（以 下简称"公司"）董事会，就公司在任独立董事杨模荣、李进华、史静的独立性 情况进行评估并出具如下专项意见： ...

2024 年度独立董事述职报告 史 静 2024 年，本人担任合肥立方制药股份有限公司（以下简称"公司"）第五届 董事会独立董事。作为公司独立董事，本人严格按照《中华人民共和国公司法》 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》《上市公司治理准则》等法律、法规以及《公司章 程》《独立董事工作制度》等规定要求开展工作，诚信、勤勉、尽责、忠实地履 行职责，积极维护公司利益和股东的合法权益，较好地发挥了独立董事作用。 现将本人 2024 年度的履职情况报告如下： 一、基本情况 本人史静，男，中国国籍，无境外永久居留权，法律硕士，并购交易师、金 融保险证券专业律师、高级律师。曾任职于合肥市供水集团、安徽易尚律师事务 所；现任安徽弘启律师事务所主任/合伙人，第十届中华全国律师代表大会代表， 安徽省律师协会常务理事，合肥市律师协会副会长，安徽财经大学客座教授，合 肥市人民政府法律顾问；曾先后被授予"全国律师行业优秀共产党员""安徽省 依法诚信规范执业示范岗律师""安徽省十佳律师"等称号。2023 年 11 月 15 日 至今，任公司独立董事。 在履职期间内，本人 ...

2024 年度独立董事述职报告 李进华 2024 年，本人作为合肥立方制药股份有限公司（以下简称"公司"）第五届 董事会的独立董事，严格按照《中华人民共和国公司法》《上市公司独立董事管 理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《上市公司治理准则》等法律、法规以及《公司章程》《独立董事工作制度》 等规定要求开展工作，诚信、勤勉、尽责、忠实地履行职责，积极维护公司利益 和股东的合法权益，较好地发挥了独立董事作用。 现将本人 2024 年度的履职情况报告如下： 一、基本情况 本人李进华，男，中国国籍，无境外永久居留权，博士、教授。曾在安徽大 学、安徽师范大学、合肥师范学院从事教学与管理工作，现任合肥师范学院二级 教授、博士生导师。为国家百千万人才、国务院特殊津贴专家、宝钢优秀教师、 安徽省杰出人才、安徽省学术技术带头人和安徽省教学名师。2022 年 8 月至今 任公司独立董事。 在履职期间内，本人任职符合《上市公司独立董事管理办法》等相关法律法 规对独立性的要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席会议情况 2024 年，公司第五届董事会共召开 6 次会议 ...

2024 年，本人作为合肥立方制药股份有限公司（以下简称"公司"）第五届 董事会的独立董事，严格按照《中华人民共和国公司法》《上市公司独立董事管 理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《上市公司治理准则》等法律、法规以及《公司章程》《独立董事工作制度》 等规定要求开展工作，诚信、勤勉、尽责、忠实地履行职责，积极维护公司利益 和股东的合法权益，较好地发挥了独立董事作用。 2024 年度独立董事述职报告 杨模荣 现将本人 2024 年度的履职情况报告如下： 一、基本情况 本人杨模荣，男，中国国籍，无境外永久居留权，博士。曾任安徽省机械设 备进出口股份有限公司销售经理；现任合肥工业大学管理学院会计系副教授，安 徽地平线建筑设计事务所股份有限公司独立董事，安徽峆一药业股份有限公司独 立董事，四创电子股份有限公司独立董事。2020 年 9 月至今任公司独立董事。 在履职期间内，本人任职符合《上市公司独立董事管理办法》等相关法律法 规对独立性的要求，不存在影响独立性的情况。 二、年度履职情况 （一）出席会议情况 2024 年，公司第五届董事会共召开 6 次会议，本人均亲自参加， ...

合肥立方制药股份有限公司 章 程 二〇二五年四月 | 第一章 | 总 | 则 | 1 | | --- | --- | --- | --- | | 第二章 | | 经营宗旨和范围 | 2 | | 第三章 | 股 | 份 | 2 | | 第一节 | | 股份发行 | 2 | | 第二节 | | 股份增减和回购 | 4 | | 第三节 | | 股份转让 | 5 | | 第四章 | | 股东和股东大会 | 5 | | 第一节 | | 股 东 | 6 | | 第二节 | | 股东大会的一般规定 | 8 | | 第三节 | | 股东大会的召集 | 11 | | 第四节 | | 股东大会的提案和通知 | 12 | | 第五节 | | 股东大会的召开 | 14 | | 第六节 | | 股东大会的表决和决议 | 16 | | 第五章 | | 董事会 | 21 | | 第一节 | | 董 事 | 21 | | 第二节 | | 董事会 | 24 | | 第六章 | | 总经理及其他高级管理人员 | 34 | | 第七章 | | 监事会 | 36 | | 第一节 | | 监 事 | 36 | | 第二节 | | 监事会 | 37 | ...

Financial Performance - The company's revenue for Q1 2025 reached ¥360,228,684.63, representing a 7.98% increase compared to ¥333,618,253.50 in the same period last year[3] - Net profit attributable to shareholders was ¥38,250,279.27, a 25.94% increase from ¥30,372,220.01 year-on-year[3] - Basic and diluted earnings per share rose to ¥0.20, reflecting a 25.00% increase from ¥0.16 in the same period last year[3] - Operating profit for the current period was ¥44,108,590.09, compared to ¥29,015,119.09 in the previous period, indicating a significant increase of 52.1%[26] - Net profit for the current period was ¥39,275,579.73, a 43.0% increase from ¥27,455,521.45 in the previous period[26] - Total comprehensive income for the period reached ¥39,275,579.73, up from ¥27,455,521.45 in the previous period, representing a growth of approximately 43.1%[27] Cash Flow - The net cash flow from operating activities increased by 132.91% to ¥36,061,213.31, up from ¥15,482,874.04 in the previous year[3] - Cash inflow from operating activities totaled ¥430,690,872.38, an increase from ¥381,665,137.63, reflecting a growth of approximately 12.8%[27] - Cash flow from investing activities showed a net outflow of ¥19,028,476.88, an improvement from a net outflow of ¥328,421,286.75 in the previous period[28] - The company’s net cash increase for the period was -¥25,407,114.22, a significant improvement from -¥315,371,864.11 in the prior period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,596,058,497.33, a slight increase of 0.39% from ¥2,585,975,314.11 at the end of the previous year[3] - Total liabilities decreased to ¥644,354,707.70 from ¥673,376,707.67, a reduction of 4.3%[23] - The company's equity attributable to shareholders increased by 2.19% to ¥1,775,966,833.09 from ¥1,737,886,950.36 at the end of the previous year[3] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,706, with the largest shareholder holding 27.09% of the shares[12] - The company completed the repurchase and cancellation of 311,263 restricted shares, reducing total share capital from 191,571,763 shares to 191,260,500 shares, representing a 0.16% decrease[16] - The company distributed cash dividends of RMB 2 per 10 shares, totaling RMB 38,252,100 (including tax) based on a total share capital of 191,260,500 shares[16] Research and Development - Research and development expenses for the current period were ¥19,080,113.30, down from ¥23,546,764.47, a decrease of 18.9%[26] - The company was awarded the "High-tech Enterprise Certificate," valid for three years, enhancing its innovation capabilities[17] - The company signed an agreement with Hefei Cube Investment Group to cultivate innovative drug research projects, ensuring priority manufacturing rights for successful products[18] Other Income and Expenses - The company received government subsidies amounting to ¥7,529,093.45, contributing to the increase in other income by 427.78%[4][9] - The company reported a significant decrease in financial expenses by 48.85% to -¥22.56, primarily due to reduced interest income from deposits[9] Current Assets - The company’s total current assets as of March 31, 2025, amounted to RMB 1,193,930,238.63, showing a slight increase from RMB 1,185,494,963.22 at the beginning of the period[21] - The company’s accounts receivable increased to RMB 403,172,219.46 from RMB 369,023,105.03, reflecting a growth of approximately 9.2%[21] - The company’s inventory as of March 31, 2025, was RMB 233,749,768.41, up from RMB 220,484,038.25, indicating an increase of about 6.3%[21] - The company’s long-term equity investments rose to RMB 176,967,615.55 from RMB 174,675,297.68, marking an increase of approximately 1.3%[21] - The company’s fixed assets decreased to RMB 678,069,352.10 from RMB 692,904,360.14, representing a decline of about 2.1%[21]

Financial Performance - The company's operating revenue for 2024 was ¥1,518,486,284.88, a decrease of 20.11% compared to ¥1,900,789,181.92 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥160,597,316.84, down 29.15% from ¥226,672,720.79 in 2023[17]. - The basic earnings per share for 2024 was ¥0.84, representing a decline of 28.81% compared to ¥1.18 in 2023[17]. - The company's total assets increased by 4.12% to ¥2,585,975,314.11 at the end of 2024, up from ¥2,483,679,575.17 at the end of 2023[17]. - The net assets attributable to shareholders rose by 3.11% to ¥1,737,886,950.36 at the end of 2024, compared to ¥1,685,526,341.61 at the end of 2023[17]. - The company reported a net cash flow from operating activities of ¥197,532,742.77 in 2024, a slight decrease of 3.02% from ¥203,674,986.89 in 2023[17]. - The company achieved total revenue of 1.518 billion yuan, a decrease of 20.11% compared to 2023, primarily due to the exclusion of a subsidiary from the consolidated financial statements[46]. - The pharmaceutical industrial segment generated revenue of 1.377 billion yuan, representing a year-on-year growth of 18.92%[46]. - The company’s pharmaceutical products accounted for 98.00% of total revenue, with a decline of 21.12% compared to the previous year[57]. - The domestic revenue was CNY 1.516 billion, down 20.16% from the previous year, while overseas revenue increased by 14.30% to CNY 2.80 million[57]. Research and Development - The company has maintained its commitment to research and development of new drugs, focusing on innovative and improved formulations[10]. - The company is focusing on innovation in drug development, particularly in the areas of controlled-release formulations and modern traditional Chinese medicine[30]. - The company has established a controlled-release formulation technology platform, focusing on the development and industrialization of osmotic pump formulations, with several products already on the market, including Oxycodone Hydrochloride Controlled-Release Tablets (10mg, 40mg) and others[31]. - The company has a strong product pipeline with a focus on innovative drug development, including psychotropic and anesthetic drugs, as well as traditional Chinese medicine[37]. - The company has implemented a multi-type R&D model, including independent research, technology transfer, and collaborative research, to enhance its technological reserves in various therapeutic areas[37]. - Research and development expenses increased by 8.03% to CNY 91.78 million in 2024[55]. - The company plans to launch the three-layer core osmotic pump formulation of methylphenidate controlled-release tablets by 2025[50]. - The company has received multiple approvals for the research and development of a series of controlled substances, aiming to enhance its product pipeline in this area[96]. Operational Strategy - The company emphasizes its focus on maintaining a stable supply of essential medicines as part of its operational strategy[10]. - The company has established a procurement model that includes both self-produced raw materials and external sourcing, with a focus on quality audits of suppliers[38]. - The company’s retail procurement strategy considers brand advantages and profit margins, selecting suppliers based on sales performance and inventory needs[39]. - The company is focusing on the development of green chemical synthesis for raw materials and formulations, enhancing its competitive edge in the market[52]. - The company plans to continue expanding its research capabilities and product offerings in the pharmaceutical sector[54]. - The company is committed to optimizing its production capacity and ensuring supply according to market demand, while enhancing production technology to reduce costs[101]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, complying with legal requirements[121]. - The company maintains independent operations in assets, personnel, finance, and business, ensuring no interference from the controlling shareholder[126]. - The company has an independent financial accounting department and does not share bank accounts with the controlling shareholder[130]. - The company has established effective organizational structures, including a shareholders' meeting, board of directors, and supervisory board, which operate independently[131]. - The company ensures timely and accurate information disclosure through designated media, enhancing transparency and communication with investors[124]. - The company has a clear strategy for independent operation and decision-making, ensuring no business dependency on major shareholders[132]. - The company has established a management system for subsidiaries and joint ventures to enhance control and integration[178]. Environmental Compliance - The company has obtained environmental permits for its facilities, with the latest permit for the Wanquan Road plant valid until June 19, 2028[185]. - The company reported no exceedances in pollutant emissions during the reporting period, maintaining compliance with environmental standards[188]. - The company has implemented strict environmental protection measures, ensuring all projects received necessary approvals and passed environmental assessments[185]. - The company invested a total of 11.86 million yuan in environmental governance and protection, with 1.92 million yuan allocated for pollutant treatment and 3.14 million yuan for environmental equipment and engineering[193]. - The company has developed an emergency response plan for environmental incidents, which has been filed and includes risk assessment and resource investigation reports[192]. Shareholder Engagement - The company plans to distribute a cash dividend of 3.0 RMB per 10 shares to all shareholders, based on a total of 191,260,500 shares[4]. - The company distributed a cash dividend of RMB 5.00 per 10 shares, totaling RMB 79,821,568 (including tax) on May 28, 2024[163]. - The company also increased its share capital by 31,928,627 shares, resulting in a new total of 191,571,763 shares after the capital increase[163]. - The company has a clear and transparent cash dividend policy, ensuring that shareholder rights are protected and that the decision-making process is compliant with regulations[165]. - The total distributable profit amounts to RMB 877,118,057.73, with the cash dividend representing 100% of the total profit distribution[166]. Employee Management - The company has a total of 1,456 employees, with 484 in production, 431 in sales, 299 in technical roles, 40 in finance, and 202 in administration[158]. - The company has established a comprehensive salary system and assessment mechanism based on job responsibilities and performance, ensuring fair internal compensation distribution[159]. - The company emphasizes talent training as a strategic advantage, maintaining partnerships with training institutions for ongoing employee development[160]. - The company’s stock incentive plan for senior management includes a combination of annual salary and performance-based compensation, with restricted shares granted in 2022 and 2023[176]. Risk Management - The company acknowledges the risks associated with industry policy changes, product price reductions, and talent shortages, and is actively working to mitigate these risks[106][107][108]. - The company emphasizes the importance of environmental compliance and safety production management to minimize operational risks[111][112].

证券代码：003020 证券简称：立方制药 公告编号：2025-020 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司董事会对公司、控股股东和实际控制人就相 关事项进行了核实，有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 合肥立方制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 合肥立方制药股份有限公司（以下称"公司"）（股票简称：立方制药，股票代 码：003020）股票于 2025 年 4 月 17 日、2025 年 4 月 18 日连续两个交易日收盘价格 涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》的相关规定，属于股 票交易异常波动情形。 五、备查文件 4、公司、控股股东及实际控制人不存在关于公司的应披露而未披露的重大事项， 或处于筹划阶段的重大事项； 5、股票异常波动期间，公司控股股 ...

金十数据4月17日讯，治疗多动症药物获批，立方制药股价实现三连板。记者致电立方制药，工作人员 表示， 目前的政策来讲一般是不会进入集采。至于销售计划，该人员表示，销售部门那边会有，证券 部目前未有相关信息。 （21财经） 治疗多动症药物获批，股价实现三连板！立方制药回应 ...

近日该股表现 立方制药盘中涨停，已连收3个涨停板，截至9:26，该股报25.31元，换手率0.42%，成交量57.60万股， 成交金额1457.80万元，涨停板封单金额为5.56亿元。连续涨停期间，该股累计上涨33.07%，累计换手 率为11.02%。最新A股总市值达48.41亿元，A股流通市值34.94亿元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜1次，买卖居前营业部 中，深股通累计净卖出809.65万元，营业部席位合计净卖出606.02万元。 2024年10月30日公司发布的三季报数据显示，前三季度公司共实现营业总收入11.25亿元，同比下降 26.20%，实现净利润1.19亿元，同比下降30.57%。（数据宝） | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.04.16 | 9.99 | 3.83 | 633.01 | | 2025.04.15 | 9.99 | 6.77 | 4012.12 | | 2025.04.14 | 0.48 | 1.08 | -181.00 | ...